Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: Is it feasible?-Reference-Cited by-同舟云学术

Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: Is it feasible?

Published:2011-02-18 Issue:1 Volume:12 Page:
ISSN:1471-2369
Container-title:BMC Nephrology
language:en
Short-container-title:BMC Nephrol

Author:

Gabutti Luca,Nobile Filippo,Forni Valentina,Rigamonti Fabio,Weibel Nadir,Burnier Michel

Publisher

Springer Science and Business Media LLC

Subject

Nephrology

Link

http://link.springer.com/article/10.1186/1471-2369-12-11/fulltext.html

Reference33 articles.

1. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA: Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991, 50: 702-712. 10.1038/clpt.1991.210.

2. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999, 10: 2392-2395.

3. Macdougall IC: Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant. 2002, 17: 66-70. 10.1093/ndt/17.suppl_5.66.

4. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B: Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006, 1: 1211-1215. 10.2215/CJN.00730306.

5. Macdougall IC: CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005, 4: 436-440.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Individualized Anemia Therapy on Hemoglobin Stability;Clinical Journal of the American Society of Nephrology;2024-06-11

2. Biomedical System Dynamics to Improve Anemia Control With Darbepoetin Alfa in Long-Term Hemodialysis Patients;Mayo Clinic Proceedings;2014-01

3. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial;BMC Nephrology;2013-07-22

4. Éthique et simulation en santé;La simulation en santé De la théorie à la pratique;2013